Seeking Alpha

Pluristem to present PLX-PAD cell data later this month

  • Pluristem Therapeutics (PSTI +4.7%) gets an early lift from an announcement that the company will present results of a Phase 1/2 clinical trial of PLX-PAD cells for the treatment of muscle injury on January 21.
  • "Data from this clinical trial will give us information regarding other potential surgical orthopedic injuries and non-surgical sports related injuries for which our PLX-PAD cells may be beneficial," CEO Zami Aberman says. (PR)
Comments (1)
  • toosmarttofail
    , contributor
    Comments (472) | Send Message
    Buy the warrants (PSTIw) if you like this stock. You'll get 3-5x the upside, with less downside, and it's almost certain this stock will not remain flat.
    6 Jan, 04:12 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: